SANUWAVE Q4 preliminary revenue $6.6-6.8M (record), FY 2023 $20.0-20.2M (record)

SANUWAVE Health, Inc.

2023-FY EPS reported -$0.03 revenue$20,398,000

Q4 2023 preliminary revenue $6.6-6.8M, up 20-24% YoY and >30% vs Q3 2023; new quarterly record.
FY 2023 preliminary revenue $20.0-20.2M, up 19-20% YoY; record annual revenue.
UltraMist product line drove growth: Q4 UltraMist revenue up >30% sequentially, ~95% of total revenue.
Full Q4 and annual results expected to be released in late March 2024 with future guidance.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SANUWAVE Health, Inc. reported the quarter and fiscal year ended December 31, 2023 results: revenue preliminary revenues of $6.6 million to $6.8 million for the fourth quarter ended December 31, 2023.

Period: the quarter and fiscal year ended December 31, 2023
Revenue: preliminary revenues of $6.6 million to $6.8 million for the fourth quarter ended December 31, 2023
Result: preliminary results

Exact text from the filing

announced that revenues for the fourth quarter of 2023 are expected to be in the range of $6.6 to $6.8 million

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

SANUWAVE Health, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-001728

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.